EU nod for Actelion’s rare immune system cancer drug

8th March 2017 Uncategorised 0

Actelion has bagged European Union Approval for Ledaga, its treatment for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), a rare potentially life-threatening immune system cancer that appears in the skin.

More: EU nod for Actelion’s rare immune system cancer drug
Source: News